NYSE:PFE

Pfizer Inc (PFE)

25.01
+0.10 (0.40%)
as of Jul 31, 2026, 8:00:00 pm Market Open.
581 watching
0
Investor Insights
star iconAug 2, 2026, 12:00 am

This summary was created by AI, based on 23 opinions in the last 12 months.

Pfizer Inc. (PFE) is currently facing challenges following its pandemic-driven peak during which it surged due to COVID-19 vaccine sales. Experts have pointed out a lack of earnings momentum and concerns over a patent cliff, as key drugs have come off patent and the company needs to innovate to develop new blockbuster drugs. Despite these challenges, many analysts emphasize the attractive dividend yield, which remains around 6-8%. The company is pivoting towards growth areas such as obesity and oncology, and while there's a general belief that PFE is under pressure, patience from investors could yield positive results. Several insights indicate that while it may not attract immediate growth, the company’s efforts in acquisitions and drug development could eventually pay off, given time.

consensus icon
Consensus
Hold
valuation icon
Valuation
Undervalued
review icon
Similar
MRK
BUY
Strong pipeline. Republican win is good for pharmaceuticals.
BUY
Should start to see a rise.
BUY
Top quality company. Cheap. Good sector for the long term.
BUY
Sector has been hit hard. A very liquid stock.
DON'T BUY
Governments are trying to cut health care costs. Sector seems to be weak.
BUY
US pharmaceutical sector is very cheap now.
TOP PICK
Trading at less than 20 X earnings. Reasonable dividend yield. Have some new products in the pipeline.
BUY
Looks good.
TOP PICK
Likes the valuations. Good balance sheet and good earnings. Made some good acquisitions.
HOLD
Fair market value is more than share price.
BUY
Now is a good time for drug stocks.
BUY
At a good level now.
BUY
Earnings growth is sustainable.
BUY
In the midst of a large merger.
BUY
Extremely cheap. Great product line up.
Showing 796 to 810 of 885 entries